Orla Kjær-Christensen
Geen lopende functies
Profiel
Orla Kjær-Christensen worked as the Chief Operating Officer & Director at Prophylix AS and as the Manager-Marketing at Sparekassen Himmerland A from 2013 to 2014.
She holds a doctorate degree from the University of Tromso.
Eerdere bekende functies van Orla Kjær-Christensen
| Bedrijven | Functie | Einde |
|---|---|---|
Sparekassen Himmerland A/S
 Sparekassen Himmerland A/S Regional BanksFinance Sparekassen Himmerland A/S is engaged in the provision of financial and banking services. It offers financial products and services to both private and corporate clients including pension, insurance, cash management, and investment management. The company was founded in December 14, 1871 and is headquartered in Aars, Denmark. | Verkoop & Marketing | 09-01-2014 |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Operationeel Directeur | - |
Opleiding van Orla Kjær-Christensen
| University of Tromso | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Sparekassen Himmerland A/S
Sparekassen Himmerland A/S Regional BanksFinance Sparekassen Himmerland A/S is engaged in the provision of financial and banking services. It offers financial products and services to both private and corporate clients including pension, insurance, cash management, and investment management. The company was founded in December 14, 1871 and is headquartered in Aars, Denmark. | Finance |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
